Roche received a CE mark for its Accu-Chek Solo micropump system, which incorporates digital diabetes management software and allows for personalized insulin delivery.
The tube-free system consists of two parts: a semidisposable insulin micropump and a remote control displaying blood glucose monitoring and bolus advice. Users can bolus directly from the pump or from the hand-held remote and can detach and reattach the pump without wasting insulin, the company said in a statement.
“The new modular design of our Accu-Chek Solo micropump system responds to the needs of people with diabetes for more discretion and flexibility,” said Roland Diggelmann, CEO of Roche Diagnostics, in the statement. The system also connects to Roche Diabetes Care’s digital solutions, including the Accu-Chek Smart Pix system.
“This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option—so they can spend more time in their ideal target range and experience an improved quality of life,” Diggelmann added.
RELATED: Roche won't sell diabetes business—it's looking for deals to boost it instead
Roche is planning to launch a pilot commercialization phase in Austria, Poland, Switzerland and the U.K. in the coming weeks, and is currently conducting a clinical study in several European countries.
In July 2017, the Big Pharma signed a five-year deal with Accenture to build a patient-facing diabetes data analytics platform, with the goal of enabling personalized treatment recommendations through a network connecting patients, doctors, nurses, family members, payers and hospitals.
The system will also feature connected devices and other technologies that help patients measure their blood glucose and manage their diet, lifestyle, medication and physical activity. One of Roche’s latest meters sends blood glucose data via Bluetooth to a smartphone app.